New drug cocktail shows promise for tough stomach cancers

NCT ID NCT04632459

Completed Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received both drugs until their cancer worsened or side effects became too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab and ramucirumab
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced gastric cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 26 participants, so results may not apply to everyone. The drugs can cause serious side effects like immune reactions or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Locations

Samsung Medical Center

Seoul, Seoul, 06351, South Korea
Samsung Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.